A Phase 4 interventional study of pantoprazole and Pradaxa (dabigatran etexilate) in Atrial Fibrillation, sponsored by Boehringer Ingelheim. Completed at 103 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-05.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing dabigatran in Atrial Fibrillation — none open to participants now, 1 under way, none of them phase 3. Dabigatran · Atrial Fibrillation.
Among the 35 studies testing dabigatran in Atrial Fibrillation, this one is the 4th largest by enrollment, is one of 5 that started in 2011, is one of 22 in phase 4, and was the 7th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →None of the 35 studies testing dabigatran in Atrial Fibrillation is open now. The open studies under Atrial Fibrillation, anywhere →
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 7 · Phase 4 22
First in 2003; this study’s year is marked. 5 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,067 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 174 across the 35 interventional studies. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 35 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
45 studies in Atrial Fibrillation by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 45 finished, 44 (98%) have results posted.
Among the 45 studies in Atrial Fibrillation by Boehringer Ingelheim, this one is one of 4 that started in 2011, is one of 3 in phase 4, and was the 8th registered.
Boehringer Ingelheim’s Atrial Fibrillation studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 35 studies testing dabigatran in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 45 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective and open label study that aims to enroll approximately 1200 patients with non-valvular atrial fibrillation (NVAF) not previously treated with Pradaxa® and free of gastrointestinal symptoms (GIS) for at least 2 weeks prior to enrolment. Approximately 125 sites in North America will be recruited. Patients who report GIS during the 3 month treatment period will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
Drug: Pradaxa (dabigatran etexilate)
Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
Drug: pantoprazole · Drug: Pradaxa (dabigatran etexilate)
Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
Drug: Pradaxa, within 30 minutes after a meal
40 mg q.a.m, p.o.
150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
Drug page: Dabigatran
Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
The Rate of Complete Effectiveness of Initial GIS Management Strategy
The percentage of patients experiencing complete relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.
Time frame: Week 4
Rate of Partial Effectiveness of Initial GIS Management Strategies
The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) and patients taking Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
Time frame: Week 4
Combined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies
The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
Time frame: Week 4
Rate of Complete Effectiveness of Combined GIS Management Strategies
The percentage of patients experiencing complete relief of combined gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.
Time frame: Week 8
Rate of Partial Effectiveness of Combined GIS Management Strategies
The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
Time frame: Week 8
Combined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies
The percentage of patients experiencing combined of complete or partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
Time frame: Week 8
Rates of Complete Effectiveness of GIS at Each Visit.
The percentage of patients experiencing complete effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8
Rates of Partial Effectiveness of GIS at Each Visit.
The percentage of patients experiencing partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8
Rates of Complete or Partial Effectiveness of GIS at Each Visit.
The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.
Time frame: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 7 & Week 8
Time Between Symptom Onset and First Observed Complete or Partial Effectiveness and Between Symptom Onset and Last Observed Symptom
Time between symptom onset and first observed complete or partial effectiveness and between symptom onset and last observed symptom by management strategy.
Time frame: Week 8
| Milestone | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) | Pradaxa, Never Randomized |
|---|---|---|---|
| Started | 0 | 0 | 950 |
| Without experiencing gis | 0 | 0 | 854 |
| Reported gis prior to eot visit | 0 | 0 | 48 |
| Reported gis only at eot visit | 0 | 0 | 48 |
| Completed | 0 | 0 | 816 |
| Not completed | 0 | 0 | 134 |
| Withdrew: Worsening of events associate with nvaf. | 0 | 0 | 1 |
| Withdrew: Worsening of other pre-existing disease | 0 | 0 | 9 |
| Withdrew: Other adverse event | 0 | 0 | 54 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 10 |
| Withdrew: Early termination | 0 | 0 | 34 |
| Withdrew: Other than stated above | 0 | 0 | 21 |
| Milestone | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) | Pradaxa, Never Randomized |
|---|---|---|---|
| Started | 59 | 58 | 0 |
| Completed | 44 | 47 | 0 |
| Not completed | 15 | 11 | 0 |
| Withdrew: Worsening of events associate with gis | 3 | 2 | 0 |
| Withdrew: Other adverse event | 8 | 5 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Other than stated above | 1 | 3 | 0 |
| Milestone | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) | Pradaxa, Never Randomized |
|---|---|---|---|
| Started | 14 | 15 | 0 |
| Completed | 12 | 11 | 0 |
| Not completed | 2 | 4 | 0 |
| Withdrew: Worsening of events associate with gis | 1 | 1 | 0 |
| Withdrew: Other adverse event | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
The percentage of patients experiencing complete relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| The Rate of Complete Effectiveness of Initial GIS Management Strategy | 55.9 | 67.2 |
The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) and patients taking Pradaxa® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Rate of Partial Effectiveness of Initial GIS Management Strategies | 11.9 | 19.0 |
The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Combined Rate of Complete or Partial Effectiveness of Initial GIS Management Strategies | 67.8 | 86.2 |
The percentage of patients experiencing complete relief of combined gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Rate of Complete Effectiveness of Combined GIS Management Strategies | 42.9 | 33.3 |
The percentage of patients experiencing partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal at 4 weeks. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Rate of Partial Effectiveness of Combined GIS Management Strategies | 42.9 | 46.7 |
The percentage of patients experiencing combined of complete or partial relief of gastrointestinal symptoms (GIS) when taking pantoprazole 40 mg once daily in the morning (q.a.m.) vs. administration of Pradaxa ® (dabigatran etexilate) within 30 minutes after a meal. Complete effectiveness is defined as at the time of evaluation, both primary GIS and secondary GIS are all resolved. Partial effectiveness is defined as at the time of evaluation, either primary GIS is improved; or primary GIS is resolved, but there were still un-resolved secondary GIS.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Combined Rate of Complete or Partial Effectiveness of Combined GIS Management Strategies | 85.7 | 80.0 |
The percentage of patients experiencing complete effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Baseline (n= 59 , 58) | 0.0 | 0.0 |
| GIS 3 (Week 1, n= 59 , 58) | 39.0 | 51.7 |
| GIS 4 (Week 2, n= 59 , 58) | 45.8 | 55.2 |
| GIS 5 (Week 3, n= 59 , 58) | 55.9 | 60.3 |
| GIS 6 (Week 4, n= 59 , 58) | 55.9 | 67.2 |
| GIS 7 (Week 5, n= 14 , 15) | 28.6 | 40.0 |
| GIS 8 (Week 6, n= 14 , 15) | 42.9 | 40.0 |
| GIS 9 (Week 7, n= 14 , 15) | 42.9 | 33.3 |
| GIS 10 (Week 8, n= 14 , 15) | 42.9 | 33.3 |
The percentage of patients experiencing partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Baseline (n= 59 , 58) | 0.0 | 0.0 |
| GIS 3 (Week 1, n= 59 , 58) | 16.9 | 13.8 |
| GIS 4 (Week 2, n= 59 , 58) | 13.6 | 24.1 |
| GIS 5 (Week 3, n= 59 , 58) | 8.5 | 22.4 |
| GIS 6 (Week 4, n= 59 , 58) | 11.9 | 19.0 |
| GIS 7 (Week 5, n= 14 , 15) | 21.4 | 40.0 |
| GIS 8 (Week 6, n= 14 , 15) | 42.9 | 40.0 |
| GIS 9 (Week 7, n= 14 , 15) | 42.9 | 46.7 |
| GIS 10 (Week 8, n= 14 , 15) | 42.9 | 46.7 |
The percentage of patients experiencing complete or partial effectiveness of gastrointestinal symptoms (GIS) at each visit by management strategy. Evaluation of GIS was based on Last observation carried forward (LOCF) data up to the last observed time or up to adding the second management strategy.
| percentage of participants | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Baseline (n= 59 , 58) | 0.0 | 0.0 |
| GIS 3 (Week 1, n= 59 , 58) | 55.9 | 65.5 |
| GIS 4 (Week 2, n= 59 , 58) | 59.3 | 79.3 |
| GIS 5 (Week 3, n= 59 , 58) | 64.4 | 82.8 |
| GIS 6 (Week 4, n= 59 , 58) | 67.8 | 86.2 |
| GIS 7 (Week 5, n= 14 , 15) | 50.0 | 80.0 |
| GIS 8 (Week 6, n= 14 , 15) | 85.7 | 80.0 |
| GIS 9 (Week 7, n= 14 , 15) | 85.7 | 80.0 |
| GIS 10 (Week 8, n= 14 , 15) | 85.7 | 80.0 |
Time between symptom onset and first observed complete or partial effectiveness and between symptom onset and last observed symptom by management strategy.
| days | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) |
|---|---|---|
| Duration of GIS (N= 58; 58) | 23.5 ± 25.67 | 23.9 ± 25.35 |
| Time to first complete effectiveness (N= 43; 50) | 12.1 ± 13.45 | 10.7 ± 10.23 |
| Time to first partial effectiveness(N= 6; 2) | 23.7 ± 15.50 | 3.5 ± 2.12 |
Collected over From first drug administration until 6 days after end of trial, up to 158 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pradaxa, 30 Minutes After a Meal (Randomized) | — | 2/59 (3.4%) | 37/59 (62.7%) |
| Pantoprazole 40 mg (Randomized) | — | 3/58 (5.2%) | 35/58 (60.3%) |
| Pradaxa, Never Randomized | — | 109/950 (11.5%) | 161/950 (16.9%) |
| Event | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) | Pradaxa, Never Randomized |
|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/59 | 2/58 | 22/950 |
| Cardiac failure congestiveCardiac disorders | 0/59 | 1/58 | 21/950 |
| Small intestinal obstructionGastrointestinal disorders | 0/59 | 1/58 | 0/950 |
| Cardiac arrestCardiac disorders | 1/59 | 0/58 | 2/950 |
| Chest painGeneral disorders | 0/59 | 0/58 | 5/950 |
| PneumoniaInfections and infestations | 0/59 | 0/58 | 5/950 |
| Renal failure acuteRenal and urinary disorders | 0/59 | 0/58 | 5/950 |
| Atrial flutterCardiac disorders | 0/59 | 0/58 | 4/950 |
| Sick sinus syndromeCardiac disorders | 0/59 | 0/58 | 4/950 |
| Coronary artery diseaseCardiac disorders | 0/59 | 0/58 | 3/950 |
| Event | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) | Pradaxa, Never Randomized |
|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 17/59 | 15/58 | 73/950 |
| Abdominal discomfortGastrointestinal disorders | 7/59 | 13/58 | 25/950 |
| EructationGastrointestinal disorders | 13/59 | 10/58 | 25/950 |
| Abdominal distensionGastrointestinal disorders | 8/59 | 12/58 | 23/950 |
| Abdominal pain upperGastrointestinal disorders | 8/59 | 10/58 | 26/950 |
| Epigastric discomfortGastrointestinal disorders | 9/59 | 10/58 | 18/950 |
| NauseaGastrointestinal disorders | 5/59 | 10/58 | 31/950 |
| RegurgitationGastrointestinal disorders | 9/59 | 4/58 | 15/950 |
| DiarrhoeaGastrointestinal disorders | 7/59 | 7/58 | 30/950 |
| FlatulenceGastrointestinal disorders | 5/59 | 5/58 | 14/950 |
Entered Set (ES): This patient set included all patients entered in the study. For those patients who were randomized to management strategies, their data prior to randomization was included in the entered set. All data from patients who were never randomized are in the entered set.
| Age, Continuous(Years) | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) | Pradaxa, Never Randomized | Total |
|---|---|---|---|---|
| Mean | 69.1 ± 11.1 | 69.6 ± 10.8 | 69.7 ± 10.7 | 69.7 ± 10.7 |
| Sex: Female, Male(Participants) | Pradaxa, 30 Minutes After a Meal (Randomized) | Pantoprazole 40 mg (Randomized) | Pradaxa, Never Randomized | Total |
|---|---|---|---|---|
| Female | 22 | 20 | 304 | 346 |
| Male | 37 | 38 | 646 | 721 |
Showing the first 100 of 103 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2011, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pantoprazole · Dabigatran